Abstract:Induction of tumor cell senescence has become a promising strategy for anti-tumor immunotherapy, but fibrotic matrix severely blocks senescence inducers penetration and immune cells infiltration. Herein, we designed a cancer-associated fibroblasts (CAFs) triggered structure-transformable nano-assembly (HSD-P@V), which can directionally deliver valsartan (Val, CAFs regulator) and doxorubicin (DOX, senescence inducer) to the specific targets. In detail, DOX is conjugated with hyaluronic acid (HA) via diselenide bonds (Se-Se) to form HSD micelles, while CAFs-sensitive peptide is grafted onto the HSD to form a hydrophilic polymer, which is coated on Val nanocrystals (VNs) surface for improving the stability and achieving responsive release. Once arriving at tumor microenvironment and touching CAFs, HSD-P@V disintegrates into VNs and HSD micelles due to sensitive peptide detachment. VNs can degrade the extracellular matrix, leading to the enhanced penetration of HSD. HSD targets tumor cells, releases DOX to induce senescence, and recruits effector immune cells. Furthermore, senescent cells are cleared by the recruited immune cells to finish the integrated anti-tumor therapy. In vitro and in vivo results show that the nano-assembly remarkably inhibits tumor growth as well as lung metastasis, and extends tumor-bearing mice survival. This work provides a promising paradigm of programmed delivering multi-site nanomedicine for cancer immunotherapy. Graphical abstract Cancer-associated fibroblasts (CAFs) triggered structure-transformable nano-assembly (HSD-P@V) was constructed for directionally delivering valsartan (Val, CAFs regulator) and doxorubicin (DOX, senescence inducer) to the specific targets, thus enhancing tumor immunotherapy. Download : Download high-res image (447KB) Download : Download full-size image

In Situ Heparan Sulfate-Induced Peptide Self-Assembly to Overcome the Cell Surface Glycocalyx Barrier for Cancer Treatment

Blocking CD47 with Restructured Peptide Nanoparticles for Motivating Phagocytosis to Inhibit Tumor Progression

Peptide-Induced Self-Assembly of Therapeutics into a Well-Defined Nanoshell with Tumor-Triggered Shape and Charge Switch

Self‐Assembly of Therapeutic Peptide into Stimuli‐Responsive Clustered Nanohybrids for Cancer‐Targeted Therapy

Intracellular Restructured Reduced Glutathione-Responsive Peptide Nanofibers for Synergetic Tumor Chemotherapy

Histone Deacetylase‐Triggered Self‐Immolative Peptide‐Cytotoxins for Cancer‐Selective Drug Delivery

Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency

Empowering hydrophobic anticancer drugs by ultrashort peptides: General Co-assembly strategy for improved solubility, targeted efficacy, and clinical application

Rationally Designed Enzyme‐Resistant Peptidic Assemblies for Plasma Membrane Targeting in Cancer Treatment

Novel Self-Assembly Endows Human Serum Albumin Nanoparticles with an Enhanced Antitumor Efficacy

Facial Solid-Phase Synthesis of Well-Defined Zwitterionic Amphiphiles for Enhanced Anticancer Drug Delivery

A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐targeting Chimeras Enhanced Immunotherapy

Turning a Luffa Protein into a Self-Assembled Biodegradable Nanoplatform for Multitargeted Cancer Therapy.

Hyaluronidase-triggered Anticancer Drug and Sirna Delivery from Cascaded Targeting Nanoparticles for Drug-Resistant Breast Cancer Therapy

Computer-Aided Design of Lasso-like Self-Assembling Anticancer Peptides with Multiple Functions for Targeted Self-Delivery and Cancer Treatments

Encapsulation of Hydrophilic and Hydrophobic Peptides into Hollow Mesoporous Silica Nanoparticles for Enhancement of Antitumor Immune Response.

Spatiotemporal transformable nano-assembly for on-demand drug delivery to enhance anti-tumor immunotherapy

Semiconducting Polymer Nanoparticles with Surface‐Mimicking Protein Secondary Structure As Lysosome‐Targeting Chimaeras for Self‐Synergistic Cancer Immunotherapy

Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy

Assemblies of Peptide-Cytotoxin Conjugates for Tumor-Homing Chemotherapy

In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy